



## Organ Transplantation, Pros, Cons, and illustrations: A Basic Awareness to the Public

\*Hindustan AbdulAhad<sup>1</sup>, Chinthaginjala Haranath<sup>1</sup>, Bhupalam Pradeepkumar<sup>2</sup>, Chittem Vinay<sup>2</sup>, Chalamatigari Yoga Chandra Sekhar Reddy<sup>2</sup>, Mitaigiri Shaik Sajid<sup>2</sup>, Balaiah Gari Mani Raja Rao<sup>2</sup>, Manjoor Ahamad Syed<sup>3</sup>, Shaik Mohammed Yusuf<sup>4</sup>

<sup>1</sup> Department of Industrial Pharmacy, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) - Autonomous, Ananthapuramu – 515721, Andhra Pradesh, India

<sup>2</sup> Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) - Autonomous, Ananthapuramu – 515721, Andhra Pradesh, India

<sup>3</sup> Department of Pharmacy, Mettu University, Mettu-2012 EC, Ethiopia.

<sup>4</sup> Department of Pharmacy, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia

### Abstract

Solid-organ transplantation saves the lives of patients affected by end-stage organ failure and enhances the quality of life. It has been developed in the last two decades and provides amazing results for children and young people and increases the growing number of elderly transplant patients with organ transplantation. Use of corticosteroids, vaccines, and other drugs to avoid infection in diseased patients. Several approaches have been developed to prolong organ obtainability, including living donor liver transplantation, split liver transplantation, and application of expanded criteria for donors and donation after circulatory death grafts. Unprincipled practices in many countries are due to the availability of organs. Organ transplantation requires screening and comparative contraindications in the recipient. The authors want to give a general awareness to the public, which is essential to know for donating and receiving organs from others.

**Keywords:** organ; transplant; compatibility; donor; recipient.

### Article Info:

Received:

February 25, 2021

Received Revised:

September 5, 2021

Accepted:

September 11, 2021

Available online:

September 11, 2021

\*Corresponding author:

abduhindustan@gmail.com

## 1. INTRODUCTION

Organ transplant (OT) is one of the suitable recommended procedures in case of organ failure and is assumed only in serious cases and alternative medical situations<sup>1</sup>. In such conditions, at the last step of organ failure, healthy organs taken from a person alive or dead are transferred to the recipient<sup>2</sup>.

Organ transfer helps patients experiencing serious infections to live a satisfied life and an increased one up to a standard lifetime<sup>3</sup>. OT may be vital in the case of inherited organ problems such as hereditary cardiac defects. In such conditions, treatment can fall short of changing a variation in tradition or lifetime of the patient.

Chronic or developed situations such as diabetes mellitus or bodily damage can also be reasons for the necessity for organ transfer surgery<sup>4</sup>. Organs for transplantation include the lungs, heart, pancreas, kidneys, liver, and intestine. The face and body are also being accepted. Kidney transplants are commonly assumed to be the most common type of OT and have a high organ transfer success rate<sup>5</sup>.

The OT method has become common over the years with old people in advanced countries, such as the USA. The organ transfer surgery procedure is a complex one, containing many mild stages and demanding a highly trained team of surgical specialists. The conditions for organ transfer include a series of exams to determine the kind of donor organ most appropriate for the recipient and prevent OT rejection<sup>6</sup>.

It is identified by specialists that a patient is undertaking the OT method, OT waiting list to await a donor organ. The conditions for transplant require severe organ failure within the recipient patient, and then being placed on the transfer list. The health of the patient is observed at regular breaks to conclude the prospect of the OT procedure once an organ becomes obtainable<sup>7</sup>.

Organ matching is a dangerous part of the OT procedure where age, gender, history, blood type matching, and many such conditions for OTs are measured at the time of placing the patient on an OT waiting list. Considering the difficulty of situations requiring OT, the guidelines surrounding the complete method are strict and frequently observed<sup>8</sup>.

## 2. HISTORY OF ORGAN TRANSPLANTATION

The original explanations of OT can be found in ancient Indian, Greek, Roman, and Chinese mythology involving bone, skin, teeth, and heart transplantation. In the 16th century, Italian surgeon Gasparo Tagliacozzi used skin transplants for plastic rebuilding<sup>9</sup>. He was the first to explain an immunologic response after the graft was received from a different person.

Early in the 20th century, French physician Alexis Carrel improved a new procedure for vascular anastomoses. Dr. Carrel did many successful kidney transfers in hounds and established a method for vessel reconstruction. In 1912, Dr. Carrel<sup>10</sup> was granted the Nobel Prize in Physiology or Medicine for his revolutionary work<sup>11</sup>.

The initial person to person transplant was introduced in 1933 in the USSR by the surgeon U.U. Voronoy<sup>12</sup>. The blood group incompatible graft was found 6h after the donor's expiry and even though the patient lived two days, the graft never formed urine. Certain significant surgical developments<sup>13</sup>, OT was a failure because of a lack of information in immunology.

The next historical record in OT is derived as the result of the efforts of the British biologist, Sir Peter Brian Medawar. He specialized in immunology. During World War II, he inspected complications in skin homograft transplantation<sup>14</sup>. On behalf of his exploration of implant rejection and development of immune forbearance, Dr. Medawar was awarded the Nobel Prize in Physiology or Medicine in 1960 and is considered the father of transplantation<sup>15</sup>.

Dr. Thomas Murray, of the same twins, did the 1<sup>st</sup> successful kidney transplant. The receiver lived 8 years with common graft rejection<sup>16</sup>. He won the Nobel Prize for Physiology or Medicine in 1990. In 1963, after a wide range of work on animal prototypes, Dr. James Hardy implemented the 1<sup>st</sup> lung transplant. The patient lived for 18 days without any proof of rejection<sup>17</sup>.

The first trial of liver transfer was conducted by Thomas Starzl and in 1967, he conducted the first successful liver transplant<sup>18</sup>. Also, in 1967, Dr. Christian Bernard transplanted the 1<sup>st</sup> human heart in South Africa. The recipient was 53 years old and lived for 18 days. After 12 months, not less than 100 heart transplants have been completed worldwide<sup>19</sup>. Unfortunately, overall life was low, majorly because of the lack of real immunosuppression.

## 3. TYPES OF ORGAN TRANSPLANTATION

OT is one of the most remarkable successes in the history of drugs. These are the various parts of the body which will be transplanted. Therefore, the rules governing OT.

### 3.1. Heart transplantation

A healthy heart from a donor who has endured cerebral death is utilized to exchange a patient's injured or unhealthy heart. Because of the multifaceted nature of this technique, severe clinical criteria are forced in evaluating whether a donor's heart is suitable for transplant and whether a possible recipient is suitable for the transfer. The utilization of cardiac grafts began in the US in 1993. Even though the heart has been effectively transplanted, the danger related to using these lower grafts is high. Different methodologies are at present being used for cardiovascular transplantation. This acknowledgement of an organ with minor coronary artery disease on the use of recently grafted hearts<sup>20</sup>.

### 3.2. Lung transplant

Lung transplantation is a medical procedure that replaces an ailing or failing lung with a donor's lung. As indicated by information from the Organ Procurement and Transplantation Network, there have been over 36100 lung transplants, about 80%. The long-term endurance rate is 50%. Those numbers were a lot lower 20 years ago. Lung transplantation is a possibility for individuals with end-stage lung infections like COPD, pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension, sarcoidosis, and other more uncommon lung diseases<sup>21, 22</sup>.

### 3.3. Liver transplant

A diseased person's liver is replaced with a healthy liver graft from a donor. Several approaches have been developed to prolong organ obtainability, including living donor liver transplantation (LDLT), split liver transplantation, and the application of ECD and DCD grafts. In renal grafts, the living contribution of hepatic grafts is meaningfully more complicated. Split liver transplantation offers the likelihood of achieving two transplantations with one donor. Unfortunately, this transplantation is limited to small-sized grafts and can be utilized only for children and smaller adults. There are several artificial or bio-artificial systems under exploration that may be used for bridge transplantation. A bio-engineered liver is a future thought and is presently under investigation. Liver transplantation is the second most often performed transplant after kidney transplantation<sup>23, 24</sup>.

### 3.4. Pancreas transplant

A pancreas transplant may be a surgery to put a good pancreas from a lifeless donor into an individual whose pancreas is not functioning properly. The first successful kidney and liver transplant was performed in 1966 by Dr. Richard Lillehei and Dr. William Kelly at the University of Minnesota. They performed the first singular pancreas transplant in 1968. This type is majorly used to treat type 1 diabetes. This agreement is a potential cure for this condition. In some cases, pancreas transplants may also treat type 2 diabetes and are rarely used in the treatment of pancreatic, bile duct, or other cancers. Isolated islet transplantation is a snowballing incidence and is the topic of much ongoing research<sup>25, 26</sup>.

### 3.5. Cornea transplant

A Corneal transplant helps to restore eyesight to those who have lost vision due to corneal infection. An infected or overcast cornea is often reinstated surgically with a normal cornea, donated by another individual, for the period of corneal transplantation. A cornea transplant can also ease pain and other problems related to cornea diseases. A lot of situations can be treated with a cornea transplant, including a cornea that bulges outwards (keratoconus), Fuchs's dystrophy, swelling of the cornea, and corneal ulcers not responding to treatment. Corneal transplantation is often done using general anaesthesia (GA) or local anaesthesia (LA) plus IV sedation. Topical antibiotics are used for many days postoperatively and topical corticosteroids for many months. If the full thickness of the corneal transplantation is done, it takes 18 months to achieve full visual potential because of change refraction with wound therapeutic and after suture exclusion<sup>27, 28</sup>.

### 3.6. Trachea transplant

The windpipe or trachea is a cartilaginous pipe plunging from the larynx into the bronchi and into the lungs. A trachea transplant will help patients experience toughening and tapering of their windpipe. Some of those who have sustained damage to the trachea may require a tracheotomy to restore normal breathing. Revolutionary researchers and surgeons at the Mount Sinai Health System (MSHS) have familiarized

themselves with the Tracheal and Transplant Program (TTP) intended to achieve tracheal transplantations for patients in need<sup>29,30</sup>.

### 3.7. Kidney transplant

Kidney transplantation is often taken from living donors. The first suggestion for kidney transfer is late-stage kidney failure, which has absolute contraindications including comorbidities that will make the graft persistent, which can be identified via screening, and relative contraindications include badly restricted diabetes, which may cause the failure of the allograft. Despite the use of immunosuppressants, about 20% of renal transplant recipients have one or more rejection periods less than the first year of transplantation. The biopsy will also help differentiate antibody-mediated from t-cell-mediated rejection and recognize other similar reasons for graft inadequacy or failure. Advanced tests will develop exactness of rejection diagnosis, including a dimension of urinary mRNA-encoding mediators of rejection and organic phenomena short of biopsy samples using DNA microarray. There are many areas of research goal to increase organ accessibility and survival, including optimization of ex-vivo graft perfusion and procedures for using prolonged grafts, preoperative applicant evaluation, graft and recipient matching, and pre-treatment of recipients and donors. To help with the scarcity of kidney transplantation, UNOS (United Network for Organ Sharing) has recently become familiar with a paired donation kidney transplant program. This agenda helps individuals who have perceived living donors find well-matched donors and get transplantation<sup>31,32</sup>.

### 3.8. Skin transplant

It is a proficient treatment choice for patients affected by severe burn injuries. It helps as a short-lived bandage and promotes therapeutic until a patient is prepared for grafting by using self-skin. The Skin Bank is responsible for getting well, making, and conserving donated skin for burn injuries. Skin must be recovered in less than 15 h after a donor's death, but it is frequently stored at sharp temperatures for several years. Skin grafts may be necessary. Autografts, which are split-thickness grafts used for a thin layer of the epidermis (first layer of skin) and some dermis (innermost layer of skin), are expunged, and placed on the recipient site. Full-thickness grafts used are composed of epidermis and dermis and give an improved form than split-thickness grafts. Allografts are used for patients with widespread burns or other conditions causing such enormous skin loss that the patient does not have abundant unharmed skin to provide the graft<sup>33,34</sup>.

### 3.9. Vascular tissue transplant

Transplanting vascular tissues that circulate blood around the body can help ease symptoms of panting, fatigue, and giddy spells in patients with extreme cardiovascular conditions. Vascular (blood-passing vessel) tissues are often contributed less than 24 h after death. Hopner depicted the chance of playing out the strategy in 1903; the history of vascular tissue transplantation was started by Alexis Carrel, a French biologist, physician, and researcher, viewed as an innovator in vascular medical procedures. Carrel delineated surgical techniques, including the transfer of venous areas in blood vessels in mice. In 1908, Carrel created the primary experimental vessel bank, prompting the Nobel Prize for Medicine in 1912 in appreciation of his work on vasculature and transplantation of blood vessels and organs. At the very latest, 2017, almost 85 hand and arm transfers and 20 complete or fragmented face transfers have been performed around the world<sup>35,36</sup>.

## 4. MERITS OF ORGAN TRANSPLANTATION

The advent of the concept of organ transfer came as a significant breakthrough in the 20th century medical field. The concept of organ donation is simple; it imparts a second chance to the receiver to lead a vital life. The benefits of a transplant depend on the organ a person receives. For instance, organ donation helps enhance the recipient's quality of life, when a cornea transfer restores a person's sight. However, OT is a risky operation, especially since people who need it are very rare. OT not just changed the lifetime of the beneficiary but also the lives of their loved ones (families)<sup>37</sup>.

OT thus plays an enormous role in furthering our understanding of our own body and, hence, it highly advances bioscience as we all realize it. Quality of Life Transplanting healthy organs from the human body of one person to another also helps to an excellent extent to enhance and enhance the standard of life of the recipient. A kidney transplant spectacularly increases the lifetime of a patient by about 10 years<sup>38</sup>.

Dialysis is a lifesaving treatment, but it's not a perfect substitute for actual human kidneys. Another advantage of renal transplantation could also be reduced hospital readmission. The rate of electrolyte erythrocyte sedimentation rate in deficient patients is twice that of the normal population.

The patient who has undergone a transplant will not require weekly dialysis treatment or have the side effects of dialysis such as nausea, vomiting, low blood pressure, muscle cramps and itchy skin. Transplanted cardiac patients generally have better results once they receive organs from a living donor in comparison to a lifeless donor. All solid organ transplants save the life of a patient affected by organ failure and improve the quality of life<sup>39</sup>.

## 5. PITFALLS OF ORGAN TRANSPLANTATION

OT involves operations. Transplant surgeries are always aggressive. In OT, small risks may develop. It is possible an operation can fail, a selected body can decline an organ, the tactic is completed, and a replacement organ doesn't always guarantee an enhanced life. A better risk of infections and other illnesses due to anti-rejection or other transplant-related drugs There are case studies where people have died even after a successful transplant<sup>40</sup>.

There are sure prospects of complexities emerging during the possibility of complications arising during and after the procedure that is performed to remove the organs from the body of a living contributor. Some of this entanglement may incorporate exorbitant dying, coagulating of blood, and contamination of circumstances in which the medical procedure is conducted.

While the doctors could be ready to control most of those complications, there have also been some extremely rare instances where the complications have proved to be fatal for the donor<sup>41</sup>. As an example, if one of the kidneys is donated, it would cause hypertension or kidney failure in the long-term. Similarly, a sort of lung donor might suffer from several lung complaints and a liver donor also might face various gastrointestinal troubles or a liver malfunction.

Complications associated with the use of anesthesia, including death, sometimes. All solid organ transplant recipients suffer from inherently related comorbidities such as hypertension, new-onset diabetes, cardiovascular events, infections, cancer, and in non-renal transplants, a high percentage of patients develop chronic kidney disease<sup>42</sup>.

## 6. CONCLUSIONS

Solid-organ transplantations save the lives of patients who are even in the end-stage of organ failure, and they help to enhance the quality of life. Solid organ transplantation programmers provide awesome results for children and young people, and they face challenges by extending their ratio of elderly transplant patients. The solid transplantation revolution has raised in the medical world till now and it will give us unimaginable results in the future. Organ transplantation programs have been developed in the last 20 years and are essential to the medical health care system. One of the disadvantages is the risk of unethical practices in many countries due to the availability of organs. The public media is essential to raise awareness of organ transplantation.

## ACKNOWLEDGMENTS

The authors are thankful to the RERDS-CPR of RIPER for their encouragement and support.

## CONFLICT OF INTEREST


No conflict of interest

## REFERENCES

1. Kotloff RM, Blosser S, Fulda GJ, Malinoski D, Ahya VN, Angel L, et al. Management of the potential organ donor in the ICU: society of critical care medicine/American college of chest physicians/association of organ procurement organizations consensus statement. *Critical care medicine*. 2015;43(6):1291-325.
2. Sharp LA. *Bodies, commodities, and biotechnologies: Death, mourning, and scientific desire in the realm of human organ transfer*: Columbia University Press; 2007.

3. Engle D. Psychosocial aspects of the organ transplant experience: what has been established and what we need for the future. *Journal of clinical psychology*. 2001;57(4):521-49.
4. Durstine JL, Painter P, Franklin BA, Morgan D, Pitetti KH, Roberts SO. Physical activity for the chronically ill and disabled. *Sports Medicine*. 2000;30(3):207-19.
5. Gjertson DW, Cecka JM. Living unrelated donor kidney transplantation. *Kidney international*. 2000;58(2):491-9.
6. Townsend CM, Beauchamp RD, Evers BM, Mattox KL. *Sabiston textbook of surgery E-book*: Elsevier Health Sciences; 2016.
7. Scheper-Hughes N, Alter JS, Ayora-Diaz SI, Csordas TJ, Frankenburg R, Leyton E, et al. The global traffic in human organs. *Current anthropology*. 2000;41(2):191-224.
8. Lee SG. A complete treatment of adult living donor liver transplantation: a review of surgical technique and current challenges to expand indication of patients. *American Journal of Transplantation*. 2015;15(1):17-38.
9. Ahad HA, Chinthaginjala H, Abdelaziz MA, Rahamathulla S, Jyothi Vinay Krishna et al Yellow Fungus emerging cases in India during the second wave of COVID-19". *J Pharmacy and Drug Innovations*, 2021; 2 (5): 3-9.
10. Cooper DK, editor A brief history of cross-species organ transplantation. *Baylor University Medical Center Proceedings*; 2012: Taylor & Francis.
11. Doyle AM, Lechler RI, Turka LA. Organ transplantation: halfway through the first century. *Journal of the American Society of Nephrology*. 2004;15(12):2965-71.
12. Bezinover D, Saner F. *Organ transplantation in the modern era*. Springer; 2019.
13. Anusha GB, Ahad HA, Haranath C. A technical view on transporters-the drug pharmacokinetics dictators. *MOJ Bioequivalence Bioavailability*. 2019; 6:39-45.
14. Suresh K, Ahad HA, Satyanarayana SV. Evaluation of Hepatoprotective and Antioxidant Activity of Ethanolic Extract of *Artabotrys zeylanicus* Stem against Various Hepatotoxins Induced Hepatotoxicity in Albino Wister Rats. *Journal of Pharmaceutical Research International*. 2020:25-37.
15. Rendell V, Bath NM, Brennan TV. Medawar's paradox and immune mechanisms of fetomaternal tolerance. *OBM transplantation*. 2020;4(1).
16. Linden PK. History of solid organ transplantation and organ donation. *Critical care clinics*. 2009;25(1):165-84.
17. Mendeloff EN. The history of pediatric heart and lung transplantation. *Pediatric transplantation*. 2002;6(4):270-9.
18. Starzl TE. Ethical problems in organ transplantation: a clinician's point of view. *Annals of internal medicine*. 1967;67(3\_Part\_2):32-6.
19. Strauss DC, Thomas JM. Transmission of donor melanoma by organ transplantation. *The lancet oncology*. 2010;11(8):790-6.
20. Nakatani T. Organ transplantation: heart transplantation. *Sougou Rinsyou*. 2006; 55:2053-62.
21. Keck BM, Bennett LE, Fioll BS, Daily OP, Novick RJ, Hosenpud JD. Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. *Clinical transplants*. 1998:39-52.
22. Pradeep T, Haranath C. A Review on Diabetes Mellitus Type II. *International Journal of Pharma Research & Review*. 2014 Sep;3(9):23-9.
23. Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. *New England Journal of Medicine*. 1991;325(7):454-60.
24. Adam R, Hoti E, editors. *Liver transplantation: the current situation*. *Seminars in liver disease*; 2009: © Thieme Medical Publishers.
25. Gruessner AC, Sutherland DE, Gruessner RW. Pancreas transplantation in the United States: a review. *Current opinion in organ transplantation*. 2010;15(1):93-101.
26. Black CK, Termanini KM, Aguirre O, Hawksworth JS, Sosin M. Solid organ transplantation in the 21st century. *Annals of translational medicine*. 2018;6(20).
27. Ahad HA, Haranath C, Pradeepkumar B, Ishaq BM. Hepatoprotective and antioxidant activity of ethanolic extract of *Artabotrys odoratissimus* stem on rifampicin-induced hepatotoxicity in rats. *Drug Comb Ther*. 2021;3(2):7.

28. Albar M. Organ transplantation: a Sunni Islamic perspective. *Saudi Journal of Kidney Diseases and Transplantation*. 2012;23(4):817.
29. Jain A, Bansal R. Applications of regenerative medicine in organ transplantation. *Journal of pharmacy & bioallied sciences*. 2015;7(3):188.
30. Kumar D, Cattral MS, Robicsek A, Gaudreau C, Humar A. Outbreak of pseudomonas aeruginosa by multiple organ transplantation from a common donor. *Transplantation*. 2003;75(7):1053-5.
31. Ghods AJ. The history of organ donation and transplantation in Iran. *Exp Clin Transplant*. 2014;12(suppl 1):38-41.
32. Hirsch H, Randhawa P, Practice AIDCo. BK polyomavirus in solid organ transplantation. *American Journal of Transplantation*. 2013;13(s4):179-88.
33. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. *New England Journal of Medicine*. 2003;348(17):1681-91.
34. Platt JL. New directions for organ transplantation. *Nature*. 1998;392(6679 Suppl):11-7.
35. Bedaiwy MA, Shahin AY, Falcone T. Reproductive organ transplantation: advances and controversies. *Fertility and sterility*. 2008;90(6):2031-55.
36. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation—how much of the promise has been realized? *Nature medicine*. 2005;11(6):605-13.
37. Cohen L. Where it hurts: Indian material for an ethics of organ transplantation. *Daedalus*. 1999;128(4):135-65.
38. Chapman JR. Progress in transplantation: Will it be achieved in big steps or by marginal gains? *American Journal of Kidney Diseases*. 2017;69(2):287-95.
39. Wilkinson D, Savulescu J. Should we allow organ donation euthanasia? Alternatives for maximizing the number and quality of organs for transplantation. *Bioethics*. 2012;26(1):32-48.
40. Sharp LA. Organ transplantation as a transformative experience: anthropological insights into the restructuring of the self. *Medical anthropology quarterly*. 1995;9(3):357-89.
41. Barr ML, Belghiti J, Villamil FG, Pomfret EA, Sutherland DS, Gruessner RW, et al. A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. *Transplantation*. 2006;81(10):1373-85.
42. Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease: why, who and when? Expert opinion on pharmacotherapy. 2010;11(16):2665-74.



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. To read the copy of this license please visit: <https://creativecommons.org/licenses/by-nc/4.0/>